Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157.

Barisic I, Balenovic D, Klicek R, Radic B, Nikitovic B, Drmic D, Udovicic M, Strinic D, Bardak D, Berkopic L, Djuzel V, Sever M and 6 more

Show all authors

Cvjetko I, Romic Z, Sindic A, Bencic ML, Seiwerth S, Sikiric P

Regulatory peptides14 Jan 2013Cited by 48 (Europe PMC)

PMID23327997DOI10.1016/j.regpep.2012.12.007PepBankPUB-23327997

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, all BPC‑157 regimens given 30 min before KCl regained sinus rhythm.
In plain wordsIn rats given a potassium overdose, BPC‑157 given beforehand restored normal heart rhythm.
Peptide
BPC-157
Outcome
IncreaseSinus rhythm when BPC 157 given before KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Given 30min before KCl, all BPC 157 regimens regained sinus rhythm, had less prolongation of QRS, and had no asystolic pause.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799701
02AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 given 30 min before KCl led to less prolongation of QRS.
In plain wordsIn rats given a potassium overdose, BPC‑157 given beforehand reduced a heart rhythm delay.
Peptide
BPC-157
Outcome
DecreaseQRS prolongation when BPC 157 given before KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Given 30min before KCl, all BPC 157 regimens regained sinus rhythm, had less prolongation of QRS, and had no asystolic pause.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799702
03AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 given 30 min before KCl led to no asystolic pause.
In plain wordsIn rats given a potassium overdose, BPC‑157 given beforehand prevented a heart stop.
Peptide
BPC-157
Outcome
DecreaseAsystolic pause when BPC 157 given before KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Given 30min before KCl, all BPC 157 regimens regained sinus rhythm, had less prolongation of QRS, and had no asystolic pause.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799703
04AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 given 10 min after KCl started rescue within 5-10 min and completely restored normal sinus rhythm at 1 h.
In plain wordsIn rats given a potassium overdose, BPC‑157 given afterwards restored normal heart rhythm.
Peptide
BPC-157
Outcome
IncreaseSinus rhythm when BPC 157 given after KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
BPC 157 therapy, given 10min after KCl-application, starts the rescue within 5-10min, completely restoring normal sinus rhythm at 1h.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799704
05AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 counteracted muscular weakness.
In plain wordsIn rats given a potassium overdose, BPC‑157 reduced muscle weakness.
Peptide
BPC-157
Outcome
DecreaseMuscular weakness in hyperkalemia
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Likewise, other hyperkalemia-disturbances (muscular weakness, hypertension, low sphincteric pressure) were also counteracted.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799705
06AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 counteracted hypertension.
In plain wordsIn rats given a potassium overdose, BPC‑157 reduced high blood pressure.
Peptide
BPC-157
Outcome
DecreaseHypertension in hyperkalemia
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Likewise, other hyperkalemia-disturbances (muscular weakness, hypertension, low sphincteric pressure) were also counteracted.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799706
07AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 counteracted the low pressure in the lower oesophageal and pyloric sphincters.
In plain wordsIn rats given a potassium overdose, BPC‑157 counteracted low pressure in two gut valves.
Peptide
BPC-157
Outcome
IncreaseLow sphincteric pressure in hyperkalemia
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Likewise, other hyperkalemia-disturbances (muscular weakness, hypertension, low sphincteric pressure) were also counteracted.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799707
08AnimalAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose and L-NAME, BPC‑157 always completely nullified the lesions, markedly below control levels.
In plain wordsIn rats given a potassium overdose and L-NAME, BPC‑157 fully removed the worsening effects.
Peptide
BPC-157
Outcome
DecreaseL-NAME aggravation of KCl lesions
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Mortality · Whole body
Studied dose
10 ng/kg, 10 μg/kg · intraperitonealAs given in this study (rat).
Source sentences
Summary
Accordingly with NO-system relation, deadly aggravation by L-NAME: l-arginine brings the values to the control levels while BPC 157 always completely nullified lesions, markedly below those of controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799708
09AnimalAnimal study (in vivo)Efficacy outcome
In rats given intragastric KCl, intragastric BPC‑157 fully counteracted severe stomach mucosal lesions.
In plain wordsIn rats given potassium into the stomach, BPC‑157 into the stomach fully countered the stomach lining damage.
Peptide
BPC-157
Outcome
DecreaseStomach mucosal lesions after intragastric KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 ng/kg, 10 μg/kg · intragastricAs given in this study (rat).
Source sentences
Summary
severe stomach mucosal lesions, sphincter failure and peaked T waves were fully counteracted by intragastric BPC 157 (10ng, 10μg) application, given 30min before or 10min after KCl
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799710
10AnimalAnimal study (in vivo)Efficacy outcome
In rats given intragastric KCl, intragastric BPC‑157 fully counteracted sphincter failure.
In plain wordsIn rats given potassium into the stomach, BPC‑157 into the stomach fully countered gut valve failure.
Peptide
BPC-157
Outcome
DecreaseSphincter failure after intragastric KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 ng/kg, 10 μg/kg · intragastricAs given in this study (rat).
Source sentences
Summary
severe stomach mucosal lesions, sphincter failure and peaked T waves were fully counteracted by intragastric BPC 157 (10ng, 10μg) application, given 30min before or 10min after KCl
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799711
11AnimalAnimal study (in vivo)Efficacy outcome
In rats given intragastric KCl, intragastric BPC‑157 fully counteracted peaked T waves.
In plain wordsIn rats given potassium into the stomach, BPC‑157 into the stomach fully countered an abnormal heart tracing.
Peptide
BPC-157
Outcome
DecreasePeaked T waves after intragastric KCl
Study
ratn: not reported in source
KCl-induced hyperkalemia
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/kg, 10 μg/kg · intragastricAs given in this study (rat).
Source sentences
Summary
severe stomach mucosal lesions, sphincter failure and peaked T waves were fully counteracted by intragastric BPC 157 (10ng, 10μg) application, given 30min before or 10min after KCl
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
Report a problemFND-2332799712
12LabIn vitro (cells)Mechanism
In HEK293 cells under hyperkalemic conditions, BPC‑157 directly affected potassium conductance.
In plain wordsIn cells, BPC‑157 directly affected how potassium moves through the cell membrane.
Peptide
BPC-157
Outcome
Direction not reportedPotassium conductance in hyperkalemic conditions
Study
humann: not reported in source
HEK293 cells
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In HEK293 cells, hyperkalemic conditions (18.6mM potassium concentrations), BPC 157 directly affects potassium conductance, counteracting the effect on membrane potential and depolarizations caused by hyperkalemic conditions.
Report a problemFND-2332799713
13LabIn vitro (cells)Mechanism
In HEK293 cells under hyperkalemic conditions, BPC‑157 counteracted the effect on membrane potential and depolarizations.
In plain wordsIn cells, BPC‑157 counteracted the electrical changes caused by high potassium.
Peptide
BPC-157
Outcome
DecreaseMembrane depolarization in hyperkalemic conditions
Study
humann: not reported in source
HEK293 cells
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
counteracting the effect on membrane potential and depolarizations caused by hyperkalemic conditions.
Report a problemFND-2332799714

Studies that did not test the peptide alone1

In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking BPC-157.

14AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome
In rats given KCl overdose, BPC‑157 combined with L-arginine exhibited no additive effect.
In plain wordsIn rats given a potassium overdose, adding L-arginine to BPC‑157 gave no extra benefit.
Peptide
BPC-157
Outcome
No significant changeEffect of BPC 157 combined with L-arginine
Study
ratn: not reported in source
KCl-induced hyperkalemia
Comparator
BPC 157 alone
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Combined with l-arginine, BPC 157 exhibited no additive effect
1 context sentence(design, population, supporting numbers)
Summary · context
Therapy was confronted with promptly unrelenting hyperkalemia (>12mmol/L), arrhythmias (and muscular weakness, hypertension, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min.
In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.
Report a problemFND-2332799709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157.

Summary

Results from this study14

Studies that did not test the peptide alone1

Version history

Subjects

Publication types

MeSH terms